Related Experiment Videos
Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo
1Department of Pediatrics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, USA.
Journal of Applied Toxicology : JAT
|January 1, 1997
Summary
Ifosfamide
Area of Science:
- Nephrology
- Oncology
- Biochemistry
Background:
- Ifosfamide is a chemotherapy drug.
- Ifosfamide causes kidney damage.
- Chloroacetaldehyde is a metabolite of ifosfamide and a suspected cause of kidney damage.
Purpose of the Study:
- To investigate the effects of chloroacetaldehyde on kidney function.
- To assess the protective role of mesna against chloroacetaldehyde-induced kidney injury.
Main Methods:
- Infusion of increasing amounts of chloroacetaldehyde into the kidneys of rats.
- Measurement of kidney function, glutathione levels, and malondialdehyde formation.
- Administration of mesna concurrently with chloroacetaldehyde.
Main Results:
- Chloroacetaldehyde caused dose-dependent kidney dysfunction, including reduced filtration and increased excretion of sodium, glucose, and protein.
- Kidney glutathione levels decreased, and malondialdehyde increased with chloroacetaldehyde infusion.
- Mesna partially improved kidney function and prevented malondialdehyde accumulation but did not prevent glutathione depletion.
Conclusions:
- Chloroacetaldehyde, an ifosfamide metabolite, induces kidney dysfunction, glutathione depletion, and lipid peroxidation.
- Mesna offers limited protection against chloroacetaldehyde nephrotoxicity, explaining incomplete prevention of ifosfamide-related kidney injury in patients.